影像学诊断中晚期肝癌TACE术后活性病灶
|
摘要
TACE是治疗中晚期肝癌的有效手段,但病灶残留或复发是影响TACE术后疗效的重要因素。影像学检查在TACE术后随访中具有重要作用,本文对中晚期肝癌TACE术后活性病灶的影像学诊断进展与现状进行综述。
TACE is effective for treatment of advanced liver cancer,but residual or recurrence of cancer is an important factor affecting the efficacy of TACE.Imaging assessment plays an important role in the follow-up after TACE.The advancements and the status of imaging assessment for active lesions of liver cancer after TACE were reviewed in this article.
TACE is effective for treatment of advanced liver cancer,but residual or recurrence of cancer is an important factor affecting the efficacy of TACE.Imaging assessment plays an important role in the follow-up after TACE.The advancements and the status of imaging assessment for active lesions of liver cancer after TACE were reviewed in this article.
引文
[1] Omata M, Cheng AL, Kokudo N, et al. Asia-pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update. Hepatol Int, 2017,11(4):317-370.
[2] Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 2016,64(1):106-116.
[3] Yang K, Zhang XM, Yang L, et al. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol, 2016,22(20):4835-4847.
[4] 江旭,李慧,杨继金,等.常规TACE术中DSA诊断肝细胞癌切除术后3个月内复发.中国介入影像与治疗学,2018,15(7):387-391.
[5] 杨敏玲,杨志勇,谢春明.原发性肝癌经导管肝动脉化疗栓塞术后肿瘤残留及新发病灶的CT和数字减影血管造影诊断对比研究.肿瘤研究与临床,2014,26(3):145-147,152.
[6] 赵亮,曾帅,马鋆,等.彩色编码数字减影血管造影在定量分析化疗栓塞前后肝脏肿瘤灌注减少中的应用价值.介入放射学杂志,2017,26(4):313-317.
[7] Vande Lune P, Abdel Aal AK, Klimkowski S, et al. Hepatocellular carcinoma: Diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization. J Clin Transl Hepatol, 2018,6(2):175-188.
[8] Jiang HY, Chen J, Xia CC, et al. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol, 2018,24(22):2348-2362.
[9] Moschouris H, Kalokairinou-Motogna M, Vrakas S, et al. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS). Med Ultrason, 2017,19(2):134-142.
[10] Gummadi S, Stanczak M, Lyshchik A, et al. Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization. Radiol Case Rep, 2018,13(3):713-718.
[11] 王海军,程瑞洪,王朝晖,等.超声造影在肝动脉化疗栓塞术联合微波消融治疗肝癌效果评估中的应用.北华大学学报(自然科学版),2017,18(5):645-648.
[12] Shaw CM, Eisenbrey JR, Lyshchik A, et al. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads. J Ultrasound Med, 2015,34(5):859-867.
[13] Liu QY, He CD, Zhou Y, et al. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol. 2016,22(11):3242-3251.
[14] Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol, 2014,83(9):1665-1671.
[15] Shao GL, Zheng JP, Guo LW, et al. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore), 2017,96(3):e5518.
[16] 邢古生,王爽,李忱瑞,等.宝石能谱CT成像碘含量测定法在肝细胞癌患者经动脉化疗栓塞术后随访中的应用.中华肿瘤杂志,2015,37(3):208-212.
[17] Yim SY, Park BJ, Um SH, et al. Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (Baltimore), 2016,95(39):e4903.
[18] Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol, 2013,24(4):501-508.
[19] Suk Oh J, Jong Chun H, Gil Choi B, et al. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: Usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vasc Interv Radiol, 2013,24(4):483-489.
[20] He X, Wu J, Holtorf AP, et al. Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. PLoS One, 2018,13(1):e0191095.
[21] Chen X, Xiao E, Shu D, et al. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol, 2014,26(1):109-113.
[22] Taouli B, Johnson RS, Hajdu CH, et al. Hepatocellular carcinoma: Perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol, 2013,201(4):795-800.
[23] Wu XM, Wang JF, Ji JS, et al. Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther, 2017,10:1637-1643.
[24] Lin M, Tian MM, Zhang WP, et al. Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. Onco Targets Ther, 2016,9:7029-7037.
[25] Joo I, Lee JM, Han JK, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting ageni CKD-516 in rabbit VX2 liver tumors. Radiology, 2014,272(2):417-426.
[26] Park YS, Lee CH, Kim JH, et al. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: A preliminary result. Magn Reson Imaging, 2014,32(6):638-646.
[27] Motosugi U, Ichikawa T, Koshiishi T, et al. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: A preliminary case-control study. Eur Radiol, 2013,23(1):156-162.
[28] Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J, 2006,21(4):258-264.
[29] Choi JW, Kim H, Kim HC, et al. Blood oxygen level-dependent MRI for evaluation of early response of liver tumors to chemoembolization: An animal study. Anticancer Res, 2013,33(5):1887-1892.
[30] Zhang LJ, Zhang Z, Xu J, et al. Carbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: Initial results. Oncol Lett, 2015,10(4):2009-2014.
[31] Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics, 2014,4(7):736-744.
[32] Kim MJ, Kim YS, Cho YH, et al. Use of 18F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med, 2015,30(3):308-315.
[33] Fowler KJ, Maughan NM, Laforest R, et al. PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol, 2016,39(6):855-864.
[2] Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology, 2016,64(1):106-116.
[3] Yang K, Zhang XM, Yang L, et al. Advanced imaging techniques in the therapeutic response of transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol, 2016,22(20):4835-4847.
[4] 江旭,李慧,杨继金,等.常规TACE术中DSA诊断肝细胞癌切除术后3个月内复发.中国介入影像与治疗学,2018,15(7):387-391.
[5] 杨敏玲,杨志勇,谢春明.原发性肝癌经导管肝动脉化疗栓塞术后肿瘤残留及新发病灶的CT和数字减影血管造影诊断对比研究.肿瘤研究与临床,2014,26(3):145-147,152.
[6] 赵亮,曾帅,马鋆,等.彩色编码数字减影血管造影在定量分析化疗栓塞前后肝脏肿瘤灌注减少中的应用价值.介入放射学杂志,2017,26(4):313-317.
[7] Vande Lune P, Abdel Aal AK, Klimkowski S, et al. Hepatocellular carcinoma: Diagnosis, treatment algorithms, and imaging appearance after transarterial chemoembolization. J Clin Transl Hepatol, 2018,6(2):175-188.
[8] Jiang HY, Chen J, Xia CC, et al. Noninvasive imaging of hepatocellular carcinoma: From diagnosis to prognosis. World J Gastroenterol, 2018,24(22):2348-2362.
[9] Moschouris H, Kalokairinou-Motogna M, Vrakas S, et al. Imaging of intrahepatic progression of hepatocellular carcinoma post transarterial chemoembolization. A long-term, prospective evaluation of contrast-enhanced ultrasonography (CEUS). Med Ultrason, 2017,19(2):134-142.
[10] Gummadi S, Stanczak M, Lyshchik A, et al. Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization. Radiol Case Rep, 2018,13(3):713-718.
[11] 王海军,程瑞洪,王朝晖,等.超声造影在肝动脉化疗栓塞术联合微波消融治疗肝癌效果评估中的应用.北华大学学报(自然科学版),2017,18(5):645-648.
[12] Shaw CM, Eisenbrey JR, Lyshchik A, et al. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads. J Ultrasound Med, 2015,34(5):859-867.
[13] Liu QY, He CD, Zhou Y, et al. Application of gemstone spectral imaging for efficacy evaluation in hepatocellular carcinoma after transarterial chemoembolization. World J Gastroenterol. 2016,22(11):3242-3251.
[14] Ippolito D, Fior D, Bonaffini PA, et al. Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol, 2014,83(9):1665-1671.
[15] Shao GL, Zheng JP, Guo LW, et al. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study. Medicine (Baltimore), 2017,96(3):e5518.
[16] 邢古生,王爽,李忱瑞,等.宝石能谱CT成像碘含量测定法在肝细胞癌患者经动脉化疗栓塞术后随访中的应用.中华肿瘤杂志,2015,37(3):208-212.
[17] Yim SY, Park BJ, Um SH, et al. Diagnostic performance of gadoxetic acid (Primovist)-enhanced MR imaging versus CT during hepatic arteriography and portography for small hypervascular hepatocellular carcinoma. Medicine (Baltimore), 2016,95(39):e4903.
[18] Miyayama S, Yamashiro M, Hashimoto M, et al. Identification of small hepatocellular carcinoma and tumor-feeding branches with cone-beam CT guidance technology during transcatheter arterial chemoembolization. J Vasc Interv Radiol, 2013,24(4):501-508.
[19] Suk Oh J, Jong Chun H, Gil Choi B, et al. Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma: Usefulness of contrast saturation features on cone-beam computed tomography imaging for predicting short-term tumor response. J Vasc Interv Radiol, 2013,24(4):483-489.
[20] He X, Wu J, Holtorf AP, et al. Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China. PLoS One, 2018,13(1):e0191095.
[21] Chen X, Xiao E, Shu D, et al. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol, 2014,26(1):109-113.
[22] Taouli B, Johnson RS, Hajdu CH, et al. Hepatocellular carcinoma: Perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol, 2013,201(4):795-800.
[23] Wu XM, Wang JF, Ji JS, et al. Evaluation of efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma using magnetic resonance diffusion-weighted imaging. Onco Targets Ther, 2017,10:1637-1643.
[24] Lin M, Tian MM, Zhang WP, et al. Predictive values of diffusion-weighted imaging and perfusion-weighted imaging in evaluating the efficacy of transcatheter arterial chemoembolization for hepatocellular carcinoma. Onco Targets Ther, 2016,9:7029-7037.
[25] Joo I, Lee JM, Han JK, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting ageni CKD-516 in rabbit VX2 liver tumors. Radiology, 2014,272(2):417-426.
[26] Park YS, Lee CH, Kim JH, et al. Using intravoxel incoherent motion (IVIM) MR imaging to predict lipiodol uptake in patients with hepatocellular carcinoma following transcatheter arterial chemoembolization: A preliminary result. Magn Reson Imaging, 2014,32(6):638-646.
[27] Motosugi U, Ichikawa T, Koshiishi T, et al. Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: A preliminary case-control study. Eur Radiol, 2013,23(1):156-162.
[28] Wu B, Peng WJ, Wang PJ, et al. In vivo 1H magnetic resonance spectroscopy in evaluation of hepatocellular carcinoma and its early response to transcatheter arterial chemoembolization. Chin Med Sci J, 2006,21(4):258-264.
[29] Choi JW, Kim H, Kim HC, et al. Blood oxygen level-dependent MRI for evaluation of early response of liver tumors to chemoembolization: An animal study. Anticancer Res, 2013,33(5):1887-1892.
[30] Zhang LJ, Zhang Z, Xu J, et al. Carbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: Initial results. Oncol Lett, 2015,10(4):2009-2014.
[31] Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics, 2014,4(7):736-744.
[32] Kim MJ, Kim YS, Cho YH, et al. Use of 18F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization. Korean J Intern Med, 2015,30(3):308-315.
[33] Fowler KJ, Maughan NM, Laforest R, et al. PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol, 2016,39(6):855-864.